Get started
Author

Ellen M. Reusch

Observed name: Ellen Reusch
ORCID: 0009-0006-7182-6696
Observed ORCID: 0009-0006-7182-6696
OpenAlex ID: A5035014020
A Multicenter Phase 1 Trial Evaluating Nanoliposomal Irinotecan for Heated Intraperitoneal Chemotherapy Combined with Cytoreductive Surgery for Patients with Peritoneal Surface Disease
2022 · Minsig Choi, Megan M. Harper, et al. · Annals of Surgical Oncology · 8
FASN Inhibition Enhances the Efficacy of Chemotherapy in Colorectal Cancer by Inhibiting the DNA Damage Response
2026 · Moumita Banerjee, Yekaterina Y. Zaytseva, et al. · Cancer Research · 5
PDF
Outcomes of Brain Metastasis from Lung Cancer
2025 · James M. Mobley, Kerry I. Phillips, et al. · Cancers · 5
PDF
Case Report: Advanced grade 2 meningioma with PBRM1 inactivation with prolonged response to immunotherapy
2025 · Ellen Reusch, Keng Hee Peh, et al. · Frontiers in Oncology · 2
PDF
Priming immunotherapy with radiotherapy (RT) in advanced non-small cell lung cancer (NSCLC) and head and neck squamous cell cancer (HNSCC): Interim analysis of phase II clinical trial.
2021 · Aasems Jacob, Alexander Kreimer, et al. · Journal of Clinical Oncology · 2
Supplemental Table S3 from FASN Inhibition Enhances the Efficacy of Chemotherapy in Colorectal Cancer by Inhibiting the DNA Damage Response
2026 · Moumita Banerjee, Yekaterina Y. Zaytseva, et al.
Supplemental Figure S4 from FASN Inhibition Enhances the Efficacy of Chemotherapy in Colorectal Cancer by Inhibiting the DNA Damage Response
2026 · Moumita Banerjee, Yekaterina Y. Zaytseva, et al.
Supplemental Figure S8 from FASN Inhibition Enhances the Efficacy of Chemotherapy in Colorectal Cancer by Inhibiting the DNA Damage Response
2026 · Moumita Banerjee, Yekaterina Y. Zaytseva, et al.
Supplemental Table S2 from FASN Inhibition Enhances the Efficacy of Chemotherapy in Colorectal Cancer by Inhibiting the DNA Damage Response
2026 · Moumita Banerjee, Yekaterina Y. Zaytseva, et al.
Supplemental Figure S5 from FASN Inhibition Enhances the Efficacy of Chemotherapy in Colorectal Cancer by Inhibiting the DNA Damage Response
2026 · Moumita Banerjee, Yekaterina Y. Zaytseva, et al.
Supplemental Figure S7 from FASN Inhibition Enhances the Efficacy of Chemotherapy in Colorectal Cancer by Inhibiting the DNA Damage Response
2026 · Moumita Banerjee, Yekaterina Y. Zaytseva, et al.
Supplemental Figure S6 from FASN Inhibition Enhances the Efficacy of Chemotherapy in Colorectal Cancer by Inhibiting the DNA Damage Response
2026 · Moumita Banerjee, Yekaterina Y. Zaytseva, et al.
Supplemental Figure S1 from FASN Inhibition Enhances the Efficacy of Chemotherapy in Colorectal Cancer by Inhibiting the DNA Damage Response
2026 · Moumita Banerjee, Yekaterina Y. Zaytseva, et al.
Supplemental Table S1 from FASN Inhibition Enhances the Efficacy of Chemotherapy in Colorectal Cancer by Inhibiting the DNA Damage Response
2026 · Moumita Banerjee, Yekaterina Y. Zaytseva, et al.
Supplemental Figure S2 from FASN Inhibition Enhances the Efficacy of Chemotherapy in Colorectal Cancer by Inhibiting the DNA Damage Response
2026 · Moumita Banerjee, Yekaterina Y. Zaytseva, et al.
Data from FASN Inhibition Enhances the Efficacy of Chemotherapy in Colorectal Cancer by Inhibiting the DNA Damage Response
2026 · Moumita Banerjee, Yekaterina Y. Zaytseva, et al.
Supplemental Figure S3 from FASN Inhibition Enhances the Efficacy of Chemotherapy in Colorectal Cancer by Inhibiting the DNA Damage Response
2026 · Moumita Banerjee, Yekaterina Y. Zaytseva, et al.
ASO Visual Abstract: A Multicenter, Phase 1, Trial Evaluating Nanoliposomal Irinotecan for Heated Intraperitoneal Chemotherapy Combined with Cytoreductive Surgery in Patients with Peritoneal Surface Disease
2022 · Minsig Choi, Megan M. Harper, et al. · Annals of Surgical Oncology
Works count: 18
Citation count: 22
H-index: 3
I10-index:
Year
Topic
Type